Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

The invention relates to a method for preparing molecular imprint polymers (MIP) by radical polymerization that uses at least one primer including at least two chemical functions capable of forming reactive radicals, thereby providing a locally high radical concentration for priming the polymerization on or about the imprint entity or molecule. The invention also relates to molecular imprint polymers (MIP) that can be obtained by the method of the invention, and to the use thereof in the production of biomimetic biosensors, biomimetic biochips, chemical sensors, specific adsorption separation devices, as a coating, particularly for releasing active ingredients.

The invention relates to a method for preparing molecular imprint polymers (MIP) by radical polymerization that uses at least one primer including at least two chemical functions capable of forming reactive radicals, thereby providing a locally high radical concentration for priming the polymerization on or about the imprint entity or molecule. The invention also relates to molecular imprint polymers (MIP) that can be obtained by the method of the invention, and to the use thereof in the production of biomimetic biosensors, biomimetic biochips, chemical sensors, specific adsorption separation devices, as a coating, particularly for releasing active ingredients.

A composition is prepared from a platinum-based antitumor compound and a novel compound, and the novel compound is sodium(S)-2-(dithiocarboxylate ((2S, 3R, 4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-4-(methylthio)butyrate. The novel compound in the composition could effectively chelate the platinum-based antitumor compound and reduce the various adverse effects exhibited by the platinum-based compound. The dosage of the platinum-based antitumor compound can thus be increased, and the antitumor effect can be optimized. The novel compound itself is low-toxic and it has low chelating activities with essential metals in the human body; it would not impose significant adverse effects on the human body at given doses. The composition and its application as an antitumor drug overcome some technical drawbacks of platinum-based antitumor drugs, namely severe adverse effects and the development of drug resistance during administration.

The present invention provides compounds of formula (I) for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD). ##STR00001##

Disclosed is a passivated perovskite structure containing a perovskite layer; and a hindered urea bond-based Lewis acid-base containing layer adjacent the perovskite layer. Also disclosed are solar cells containing the passivated perovskite structure.

Disclosed is a passivated perovskite structure containing a perovskite layer; and a hindered urea bond-based Lewis acid-base containing layer adjacent the perovskite layer. Also disclosed are solar cells containing the passivated perovskite structure.

The present invention relates to a novel compound and a pharmaceutical composition for preventing or treating pulmonary fibrosis, comprising the same as an active ingredient, specifically, a compound represented by Formula I below; a pharmaceutical composition for preventing or treating pulmonary fibrosis, comprising the compound as an active ingredient; method for preventing or treating pulmonary fibrosis using the pharmaceutical composition; and a food composition for preventing or improving pulmonary fibrosis, comprising the compound as an active ingredient.

##STR00001## wherein, in Formula I above, R is methyl or ethenyl.

The present invention relates to a novel compound and a pharmaceutical composition for preventing or treating pulmonary fibrosis, comprising the same as an active ingredient, specifically, a compound represented by Formula I below; a pharmaceutical composition for preventing or treating pulmonary fibrosis, comprising the compound as an active ingredient; method for preventing or treating pulmonary fibrosis using the pharmaceutical composition; and a food composition for preventing or improving pulmonary fibrosis, comprising the compound as an active ingredient.

##STR00001## wherein, in Formula I above, R is methyl or ethenyl.